2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.02

PP02.02 - Baohui Han

Pdf Summary

The study led by Baohui Han at Shanghai Chest Hospital investigates the efficacy of Ivonescimab, combined with platinum-based chemotherapy, in treating non-squamous non-small cell lung cancer (NSCLC) patients who have rare oncogenic mutations and have not responded to first-line treatments. Ivonescimab, known for its promising results in NSCLC patients with EGFR mutations, is a bi-specific antibody targeting PD-1 and VEGF, potentially offering enhanced effectiveness in cases with mutations like ROS1, KRAS, HER2, RET, MET, and BRAF, except for ALK fusions.<br /><br />The study is a phase 2 single-arm clinical trial aiming to enroll up to 30 participants between 18 to 75 years old with advanced or metastatic NSCLC. Eligible participants will have disease progression after standard treatment, at least one measurable lesion, and an ECOG performance status score of 0 or 1.<br /><br />Treatment includes administering Ivonescimab intravenously at 20 mg/kg, in combination with pemetrexed (500 mg/m^2) and carboplatin (AUC 5) every three weeks for four initial cycles. This is followed by maintenance therapy with Ivonescimab and pemetrexed, with chemotherapy dosage adjustments allowed if necessary. The therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or death, up to a maximum of 24 months.<br /><br />The primary goal of the study is to evaluate progression-free survival, while secondary objectives include measuring the objective response rate, the duration of response, and overall survival rates. This investigation addresses the potential of Ivonescimab in a niche patient group and helps broaden treatment options for advanced NSCLC after first-line therapies have failed, possibly improving prognosis and quality of life for patients with rare oncogenic drivers.

Keywords

Ivonescimab

NSCLC

platinum-based chemotherapy

oncogenic mutations

bi-specific antibody

clinical trial

progression-free survival

EGFR mutations

advanced NSCLC

Shanghai Chest Hospital